{"protocolSection": {"identificationModule": {"nctId": "NCT01265524", "orgStudyIdInfo": {"id": "CTST-21"}, "organization": {"fullName": "Sorbent Therapeutics", "class": "INDUSTRY"}, "briefTitle": "Evaluation of CLP in Heart Failure Patients With Chronic Kidney Disease", "officialTitle": "A Phase 2, Randomized, Double-Blind, Multi-center Study Comparing CLP Versus Placebo in Heart Failure Patients With Chronic Kidney Disease"}, "statusModule": {"statusVerifiedDate": "2013-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-04"}, "primaryCompletionDateStruct": {"date": "2011-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-12-20", "studyFirstSubmitQcDate": "2010-12-21", "studyFirstPostDateStruct": {"date": "2010-12-23", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-01-03", "resultsFirstSubmitQcDate": "2013-03-12", "resultsFirstPostDateStruct": {"date": "2013-03-13", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-03-12", "lastUpdatePostDateStruct": {"date": "2013-03-13", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Sorbent Therapeutics", "class": "INDUSTRY"}, "collaborators": [{"name": "Pharmaterra", "class": "UNKNOWN"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine the effects of CLP on serum potassium and signs and symptoms of fluid overload in heart failure patients with chronic kidney disease."}, "conditionsModule": {"conditions": ["Heart Failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "PREVENTION", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 113, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "CLP", "type": "ACTIVE_COMPARATOR", "description": "Investigational drug: 15 g CLP per day given as capsules", "interventionNames": ["Drug: CLP"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo, capsules", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "CLP", "description": "Oral administration", "armGroupLabels": ["CLP"]}, {"type": "DRUG", "name": "Placebo", "description": "Oral administration", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Serum Potassium", "description": "Change in serum potassium from baseline to Week 8.", "timeFrame": "Baseline and 8 weeks"}], "secondaryOutcomes": [{"measure": "Weight Loss at Week 1", "timeFrame": "Baseline and 1 week"}, {"measure": "Weight Loss at Week 2", "timeFrame": "Baseline and 2 weeks"}, {"measure": "Frequency of Marked or Disabling Exertional Dyspnea by Physician Assessment at Week 4", "description": "The frequency of marked or disabling exertional dyspnea was physician assessed based on physical exam at week 4.", "timeFrame": "4 weeks"}, {"measure": "Frequency of Marked or Disabling Exertional Dyspnea by Physician Assessment at Week 8", "description": "The frequency of marked or disabling exertional dyspnea was physician assessed based on physical exam at week 8.", "timeFrame": "8 weeks"}, {"measure": "Number of Patients Improving by at Least One NYHA Functional Class From Baseline to Week 8", "timeFrame": "Baseline and 8 weeks"}, {"measure": "6MWT Distance at Week 8", "description": "Increase in the 6 minute walk test (6MWT) distance from baseline to Week 8. The test was performed according to the American Thoracic Society (ATS)Guidelines 2002.", "timeFrame": "Baseline and 8 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Heart failure with New York Heart Association (NYHA) Classification III or IV\n* Hospitalization for heart failure decompensation associated with fluid overload within the last six months\n* Chronic kidney disease\n* Must be able to understand study procedures and willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* No hospitalization within 4 weeks of Baseline Visit\n* In the investigator's judgment, any cardiovascular, renal, hepatic, endocrine, gastrointestinal, neurological or other disease or condition that makes the patients study participation unsafe\n* History or presence of gastrointestinal conditions such as severe constipation or gastrointestinal tract strictures\n* Current dialysis patient, or anticipated need for dialysis during study participation", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Detlef Albrecht, MD", "affiliation": "Sorbent Therapeutics", "role": "STUDY_CHAIR"}], "locations": [{"city": "Yerevan", "country": "Armenia", "geoPoint": {"lat": 40.18111, "lon": 44.51361}}, {"city": "Tbilisi", "country": "Georgia", "geoPoint": {"lat": 41.69411, "lon": 44.83368}}, {"city": "Chisinau", "country": "Moldova, Republic of", "geoPoint": {"lat": 47.00556, "lon": 28.8575}}]}, "referencesModule": {"references": [{"pmid": "22613585", "type": "RESULT", "citation": "Costanzo MR, Heywood JT, Massie BM, Iwashita J, Henderson L, Mamatsashvili M, Sisakian H, Hayrapetyan H, Sager P, van Veldhuisen DJ, Albrecht D. A double-blind, randomized, parallel, placebo-controlled study examining the effect of cross-linked polyelectrolyte in heart failure patients with chronic kidney disease. Eur J Heart Fail. 2012 Aug;14(8):922-30. doi: 10.1093/eurjhf/hfs074. Epub 2012 May 21."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Although 113 subjects were randomized, 2 subjects did not receive study drug and were removed from the analysis as pre- specified in the SAP.", "groups": [{"id": "FG000", "title": "Investigational Drug: CLP", "description": "Investigational drug: 15 g CLP per day given as capsules"}, {"id": "FG001", "title": "Placebo", "description": "Placebo: capsules"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "59"}, {"groupId": "FG001", "numSubjects": "52"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "41"}, {"groupId": "FG001", "numSubjects": "46"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "6"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Investigational Drug: CLP", "description": "Investigational drug: 15g CLP per day given as capsules"}, {"id": "BG001", "title": "Placebo", "description": "Placebo: capsules"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "59"}, {"groupId": "BG001", "value": "52"}, {"groupId": "BG002", "value": "111"}]}], "measures": [{"title": "Age, Customized", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "68", "spread": "8"}, {"groupId": "BG001", "value": "70", "spread": "10"}, {"groupId": "BG002", "value": "69", "spread": "9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "40"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "71"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "75.3", "spread": "13.6"}, {"groupId": "BG001", "value": "75.1", "spread": "16.2"}, {"groupId": "BG002", "value": "75.2", "spread": "14.9"}]}]}]}, {"title": "eGFR", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ml/min/1.73m3", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "45.0", "spread": "14.2"}, {"groupId": "BG001", "value": "44.9", "spread": "17.3"}, {"groupId": "BG002", "value": "45", "spread": "15.8"}]}]}]}, {"title": "New York Heart Association (NYHA) Functional Class", "description": "NYHA Functional Classes are I, II, III, and IV A brief summary of the classes is included below. Class I: patients with cardiac disease but without resulting limitations of physical activity Class II: patients with cardiac disease with slight limitations to physical activity Class III: patients with cardiac disease with marked limitations of physical activity Class IV: patients with cardiac disease resulting in an inability to carry out physical activity without discomfort", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "II", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "III", "categories": [{"measurements": [{"groupId": "BG000", "value": "52"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "97"}]}]}, {"title": "IV", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "12"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Serum Potassium", "description": "Change in serum potassium from baseline to Week 8.", "populationDescription": "The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dl", "timeFrame": "Baseline and 8 weeks", "groups": [{"id": "OG000", "title": "Investigational Drug: CLP", "description": "Investigational drug: 15g CLP per day given as capsules"}, {"id": "OG001", "title": "Placebo", "description": "Placebo: capsules"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "46"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.15", "spread": "0.348"}, {"groupId": "OG001", "value": "0.05", "spread": "0.345"}]}]}]}, {"type": "SECONDARY", "title": "Weight Loss at Week 1", "populationDescription": "The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kg", "timeFrame": "Baseline and 1 week", "groups": [{"id": "OG000", "title": "Investigational Drug: CLP", "description": "Investigational drug: 15g CLP per day given as capsules"}, {"id": "OG001", "title": "Placebo", "description": "Placebo: capsules"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "52"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.71", "spread": "1.5"}, {"groupId": "OG001", "value": "0.11", "spread": "2.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.", "pValue": "0.014", "pValueComment": "Corrections for multiplicity were not performed and P values \\< 0.05 were considered statistically significant.", "statisticalMethod": "ANCOVA", "statisticalComment": "Continuous or ordinal data were analyzed using RM-ANCOVA using change from baseline values to compare CLP and placebo treatments.", "ciPctValue": "95", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Weight Loss at Week 2", "populationDescription": "The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kg", "timeFrame": "Baseline and 2 weeks", "groups": [{"id": "OG000", "title": "Investigational Drug: CLP", "description": "Investigational drug: 15g CLP per day given as capsules"}, {"id": "OG001", "title": "Placebo", "description": "Placebo: capsules"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "51"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.83", "spread": "1.8"}, {"groupId": "OG001", "value": "0.29", "spread": "2.3"}]}]}]}, {"type": "SECONDARY", "title": "Frequency of Marked or Disabling Exertional Dyspnea by Physician Assessment at Week 4", "description": "The frequency of marked or disabling exertional dyspnea was physician assessed based on physical exam at week 4.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Investigational Drug: CLP", "description": "Investigational drug: 15g CLP per day given as capsules"}, {"id": "OG001", "title": "Placebo", "description": "Placebo: capsules"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "47"}, {"groupId": "OG001", "value": "48"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "14"}]}]}]}, {"type": "SECONDARY", "title": "Frequency of Marked or Disabling Exertional Dyspnea by Physician Assessment at Week 8", "description": "The frequency of marked or disabling exertional dyspnea was physician assessed based on physical exam at week 8.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "8 weeks", "groups": [{"id": "OG000", "title": "Investigational Drug: CLP", "description": "Investigational drug: 15g CLP per day given as capsules"}, {"id": "OG001", "title": "Placebo", "description": "Placebo: capsules"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "46"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "12"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Improving by at Least One NYHA Functional Class From Baseline to Week 8", "populationDescription": "The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline and 8 weeks", "groups": [{"id": "OG000", "title": "Investigational Drug: CLP", "description": "Investigational drug: 15g CLP per day given as capsules"}, {"id": "OG001", "title": "Placebo", "description": "Placebo: capsules"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "46"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.", "pValue": "0.0002", "pValueComment": "Corrections for multiplicity were not performed and P values \\< 0.05 were considered statistically significant.", "statisticalMethod": "ANCOVA", "statisticalComment": "Continuous or ordinal data were analyzed using RM-ANCOVA using change from baseline values to compare CLP and placebo treatments.", "ciPctValue": "95", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "6MWT Distance at Week 8", "description": "Increase in the 6 minute walk test (6MWT) distance from baseline to Week 8. The test was performed according to the American Thoracic Society (ATS)Guidelines 2002.", "populationDescription": "The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "m", "timeFrame": "Baseline and 8 weeks", "groups": [{"id": "OG000", "title": "Investigational Drug: CLP", "description": "Investigational drug: 15g CLP per day given as capsules"}, {"id": "OG001", "title": "Placebo", "description": "Placebo: capsules"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "46"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "39.3", "spread": "53.39"}, {"groupId": "OG001", "value": "19.7", "spread": "39.17"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "The efficacy and the safety analyses were done using the ITT population with Week 8/EOS data for the patients who did not complete the 8-week treatment period excluded. The ITT population included all randomized patients who received at least 1 dose of study drug.", "pValue": "0.072", "pValueComment": "Corrections for multiplicity were not performed and P values \\< 0.05 were considered statistically significant.", "statisticalMethod": "ANCOVA", "statisticalComment": "Continuous or ordinal data were analyzed using RM-ANCOVA using change from baseline values to compare CLP and placebo treatments.", "ciPctValue": "95", "ciNumSides": "TWO_SIDED"}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "eventGroups": [{"id": "EG000", "title": "Investigational Drug: CLP", "description": "Investigational drug: 15g CLP per day given as capsules", "seriousNumAffected": 4, "seriousNumAtRisk": 59, "otherNumAffected": 21, "otherNumAtRisk": 59}, {"id": "EG001", "title": "Placebo", "description": "Placebo: capsules", "seriousNumAffected": 1, "seriousNumAtRisk": 52, "otherNumAffected": 13, "otherNumAtRisk": 52}], "seriousEvents": [{"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (14.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 59}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 52}]}, {"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (14.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 59}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 52}]}, {"term": "Sudden death", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (14.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 59}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 52}]}, {"term": "Renal failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (14.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 59}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 52}]}], "otherEvents": [{"term": "Abdominal discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (14.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 59}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 52}]}, {"term": "Abdominal distention", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (14.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 59}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 52}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (14.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 59}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 52}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (14.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 59}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 52}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (14.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 59}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 52}]}, {"term": "Decreased appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (14.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 59}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 52}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (14.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 59}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 52}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (14.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 52}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (14.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 59}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 52}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "A standard confidentiality agreement is in place."}, "pointOfContact": {"title": "Howard Dittrich, MD FACC", "organization": "Sorbent Therapeutics", "email": "hdittrich@sorbent.com", "phone": "858-405-1429"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000007674", "term": "Kidney Diseases"}, {"id": "D000051436", "term": "Renal Insufficiency, Chronic"}, {"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000014570", "term": "Urologic Diseases"}, {"id": "D000052776", "term": "Female Urogenital Diseases"}, {"id": "D000005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}, {"id": "D000052801", "term": "Male Urogenital Diseases"}, {"id": "D000051437", "term": "Renal Insufficiency"}, {"id": "D000002908", "term": "Chronic Disease"}, {"id": "D000020969", "term": "Disease Attributes"}, {"id": "D000010335", "term": "Pathologic Processes"}], "browseLeaves": [{"id": "M10698", "name": "Kidney Diseases", "asFound": "Kidney Disease", "relevance": "HIGH"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M26717", "name": "Renal Insufficiency, Chronic", "asFound": "Chronic Kidney Disease", "relevance": "HIGH"}, {"id": "M26718", "name": "Renal Insufficiency", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M17319", "name": "Urologic Diseases", "relevance": "LOW"}, {"id": "M2875", "name": "Urogenital Diseases", "relevance": "LOW"}, {"id": "M27093", "name": "Female Urogenital Diseases", "relevance": "LOW"}, {"id": "M14127", "name": "Pregnancy Complications", "relevance": "LOW"}, {"id": "M8399", "name": "Female Urogenital Diseases and Pregnancy Complications", "relevance": "LOW"}, {"id": "M27095", "name": "Male Urogenital Diseases", "relevance": "LOW"}, {"id": "M6147", "name": "Chronic Disease", "relevance": "LOW"}, {"id": "M22700", "name": "Disease Attributes", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BXS", "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": true}